An Obesity Drug Prevents Covid Deaths, Study Suggests
August 30, 2024
(New York Times) – People taking Wegovy were not protected from infection. But in a large trial, their death rates were markedly lower, for reasons that are not clear.
Wegovy, the popular obesity drug, may have yet another surprising benefit. In a large clinical trial, people taking the drug during the pandemic were less likely to die of Covid-19, researchers reported on Friday.
People on Wegovy still got Covid, and at the same rate as people randomly assigned to take a placebo. But their chances of dying from the infection plunged by 33 percent, the study found. And the protective effect occurred immediately — before participants had lost significant amounts of weight. (Read More)